OGN Quote, Financials, Valuation and Earnings

Alnylam Pharmaceuticals has a net margin of 6.85% compared to Organon &'s net margin of -14.12%. Organon &'s return on equity of 397.42% beat Alnylam Pharmaceuticals's return on equity of --.

Organon & has a consensus price target of $20.00, signalling upside risk potential of 35.87%. On the other hand Alnylam Pharmaceuticals has an analysts' consensus of $314.17 which suggests that it could grow by 17.74%. Given that Organon & has higher upside potential than Alnylam Pharmaceuticals, analysts believe Organon & is more attractive than Alnylam Pharmaceuticals.

Organon & has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals has a beta of 0.300, suggesting its less volatile than the S&P 500 by 70.047%.

Organon & has a quarterly dividend of $0.28 per share corresponding to a yield of 7.61%. Alnylam Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Organon & pays 34.38% of its earnings as a dividend. Alnylam Pharmaceuticals pays out -- of its earnings as a dividend. Organon &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Organon & quarterly revenues are $1.6B, which are larger than Alnylam Pharmaceuticals quarterly revenues of $593.2M. Organon &'s net income of $109M is higher than Alnylam Pharmaceuticals's net income of -$83.8M. Notably, Organon &'s price-to-earnings ratio is 4.42x while Alnylam Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organon & is 0.60x versus 15.15x for Alnylam Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Blueprint Medicines has a net margin of 6.85% compared to Organon &'s net margin of -34.13%. Organon &'s return on equity of 397.42% beat Blueprint Medicines's return on equity of -24.43%.

Organon & has a consensus price target of $20.00, signalling upside risk potential of 35.87%. On the other hand Blueprint Medicines has an analysts' consensus of $126.48 which suggests that it could grow by 40.51%. Given that Blueprint Medicines has higher upside potential than Organon &, analysts believe Blueprint Medicines is more attractive than Organon &.

Organon & has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Blueprint Medicines has a beta of 0.746, suggesting its less volatile than the S&P 500 by 25.37%.

Organon & has a quarterly dividend of $0.28 per share corresponding to a yield of 7.61%. Blueprint Medicines offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Organon & pays 34.38% of its earnings as a dividend. Blueprint Medicines pays out -- of its earnings as a dividend. Organon &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Organon & quarterly revenues are $1.6B, which are larger than Blueprint Medicines quarterly revenues of $146.4M. Organon &'s net income of $109M is higher than Blueprint Medicines's net income of -$50M. Notably, Organon &'s price-to-earnings ratio is 4.42x while Blueprint Medicines's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organon & is 0.60x versus 11.22x for Blueprint Medicines. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of 6.85% compared to Organon &'s net margin of -2357.27%. Organon &'s return on equity of 397.42% beat Palatin Technologies's return on equity of --.

Organon & has a consensus price target of $20.00, signalling upside risk potential of 35.87%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 1200.63%. Given that Palatin Technologies has higher upside potential than Organon &, analysts believe Palatin Technologies is more attractive than Organon &.

Organon & has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.

Organon & has a quarterly dividend of $0.28 per share corresponding to a yield of 7.61%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Organon & pays 34.38% of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend. Organon &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Organon & quarterly revenues are $1.6B, which are larger than Palatin Technologies quarterly revenues of $350K. Organon &'s net income of $109M is higher than Palatin Technologies's net income of -$2.4M. Notably, Organon &'s price-to-earnings ratio is 4.42x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organon & is 0.60x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of 6.85% compared to Organon &'s net margin of 31.35%. Organon &'s return on equity of 397.42% beat Vertex Pharmaceuticals's return on equity of -3.23%.

Organon & has a consensus price target of $20.00, signalling upside risk potential of 35.87%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $497.84 which suggests that it could grow by 2.97%. Given that Organon & has higher upside potential than Vertex Pharmaceuticals, analysts believe Organon & is more attractive than Vertex Pharmaceuticals.

Organon & has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.504, suggesting its less volatile than the S&P 500 by 49.617%.

Organon & has a quarterly dividend of $0.28 per share corresponding to a yield of 7.61%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Organon & pays 34.38% of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend. Organon &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Organon & quarterly revenues are $1.6B, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.9B. Organon &'s net income of $109M is lower than Vertex Pharmaceuticals's net income of $913M. Notably, Organon &'s price-to-earnings ratio is 4.42x while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organon & is 0.60x versus 11.38x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.